Skip to content

Palvella Therapeutics

US · PVLA #2822 by market cap Listed 1970
142.85 -2.92 -2.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 11.26 Expensive vs history 84th percentile
5-year average 6.35 · #465 of 514 in Biotechnology
P/E ratio -27.57 Cheap vs history 27th percentile
5-year average -14.32 · forward -14.93
P/S ratio --
5-year average 0.00 · forward 436.40

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Palvella Therapeutics (PVLA) 2.09B -25.83 10.55 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value169.90 Economic moatNone UncertaintyHigh

Trading 18.9% below Morningstar's fair value estimate.

Fair value

Palvella Therapeutics Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% discount to our quantitative fair value estimate of $169.90 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet bolsters our estimated fair value. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -8.1, which falls in the bottom 10% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.4%, for example, lies in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Palvella Therapeutics discussion 0 comments

Add a comment